13therapeutics Completes Pre-IND Meeting with the FDA0

Portland, OR (PRWEB) December 30, 2010

13therapeutics, Inc., a bio-pharmaceutical organization that develops peptides to deal with a selection of inflammatory and automobile-immune program illnesses, announced right now that the organization has finished a Sort B pre-investigational new drug (Pre-IND) meeting with the U.S. Meals and Drug Administration (FDA) to determine the clinical and regulatory pathway to progress its anti-inflammatory peptide, P13, for topical remedy of Acute Otitis Media (AOM) and Otitis Media with Effusion (OME).

AOM is the most regular diagnosis in youngsters with above 21 million cases every single 12 months in the U.S. and annual expenses of above $ 5 billion. AOM benefits in inflammation and fluid retention inside the middle ear and Eustachian tube which can lead to hearing reduction, delayed speech and language advancement, recurrent infections, and expensive ear tubes. AOM is the most typical indication for which an antibiotic is approved to youngsters, but antibiotics have been shown to have limited therapeutic worth. Antibiotic resistant bacteria are a key public wellness worry, and antibiotics do not affect fluid retention in the center ear.

“There is a key unmet healthcare need for a clinical therapeutic for AOM and OME that lowers middle ear inflammation and fluid and connected hearing impairment and sequelae, which includes finding out impairment,” said Tom Bruggere, CEO of 13therapeutics. “In pre-clinical types of AOM and OME, P13 has been demonstrated to be an successful inhibitor of center ear inflammation, to significantly lessen center ear fluid retention, and to decrease listening to impairment.”

“We are quite pleased with the outcome of our Pre-IND interaction with the FDA,” commented Dr. Steven Hefeneider, President and CSO of 13therapeutics. “The FDA was very supportive of our efforts to progress a topical (ear drop) treatment for AOM and OME. As a outcome of the feedback we obtained on our Pre-IND package deal, we believe we have apparent visibility for the required pathway to comprehensive our toxicity testing for P13.”

Founded in 2008, Portland, Oregon-based 13therapeutics has developed a portfolio of peptides with demonstrated immune-regulatory activity and with different mechanisms of action. Many of the company’s peptides are capable of numerous approaches of delivery, have demonstrated serum stability, and have other wanted capabilities of clinical therapeutics. The management group and study experts of 13therapeutics are veterans of bioscience, research and technology. Internet site: http://www.13therapeutics.com.

###

Connected Listening to Impairments Press Releases